Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20$791 million, an increase of 7% compared to the same period in 2024 ® Opzelura (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period ® Hematology-Oncology portfolio net prod ...